Trial Profile
Evaluation of serum protein levels as potential biomarkers to predict clinical benefit in advanced non-small cell lung cancer patients treated with nivolumab
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Apr 2020
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 20 Apr 2018 New trial record
- 18 Apr 2018 Results presented at the 109th Annual Meeting of the American Association for Cancer Research